Daily phosphodiesterase type 5 inhibitors plus acetylsalicylic acid improve curvature progression and pain intensity during the active phase of peyronie's disease
{{output}}
The purpose of this study is that the combination effects of Peyronie's disease (PD) therapy with Phosphodiesterase type 5 inhibitors (PDE5i) plus acetylsalicylic acid on improve curvature progression and pain in the active phase of disease. We performed a re... ...
